MicroRNA-375 As a Potential Serum Biomarker for the Diagnosis, Prognosis, and Chemosensitivity Prediction of Osteosarcoma

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2017 Nov 9

PMID 29115164

Citations 31

Authors

Wei Liu

Xiaotao Zhao

Ying-Jian Zhang

Guang-Wen Fang

Yuan Xue

Affiliations

Soon will be listed here.

Abstract

Objective This study was performed to examine serum microRNA-375 (miR-375) expression in patients with osteosarcoma and determine its diagnostic and prognostic value. Methods Serum samples were obtained from 95 patients with osteosarcoma and 95 healthy individuals. miR-375 expression was detected by real-time polymerase chain reaction. The associations of serum miR-375 expression with the patients' clinicopathological characteristics and prognosis were then evaluated. Receiver operating characteristic curve analysis was performed to obtain the potential value of serum miR-375 as a biomarker for osteosarcoma diagnosis and chemosensitivity prediction. Results Serum miR-375 expression was significantly lower in patients with osteosarcoma than in healthy individuals. Low serum miR-375 levels were associated with advanced clinical stages, large tumor size, positive distant metastasis, and poor tumor response to preoperative chemotherapy. Receiver operating characteristic curve analysis illustrated that serum miR-375 could distinguish patients with osteosarcoma from healthy individuals and distinguish patients with a good pathologic response from those with a poor response. Multivariate analysis confirmed low serum miR-375 expression as a statistically significant independent unfavorable prognostic factor. Conclusions Serum miR-375 expression was downregulated in patients with osteosarcoma and might serve as a biomarker for its diagnosis, prognosis, and chemosensitivity prediction.

Citing Articles

MicroRNA signatures in osteosarcoma: diagnostic insights and therapeutic prospects.

Dey M, Skipar P, Bartnik E, Piatkowski J, Sulejczak D, Czarnecka A Mol Cell Biochem. 2024; .

PMID: 39419925 DOI: 10.1007/s11010-024-05135-5.

A comprehensive overview of liquid biopsy applications in pediatric solid tumors.

Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J NPJ Precis Oncol. 2024; 8(1):172.

PMID: 39097671 PMC: 11297996. DOI: 10.1038/s41698-024-00657-z.

The Landscape of microRNAs in Bone Tumor: A Comprehensive Review in Recent Studies.

Raoufinia R, Afrasiabi P, Dehghanpour A, Memarpour S, Sayyed Hosseinian S, Saburi E Microrna. 2024; 13(3):175-201.

PMID: 39005129 DOI: 10.2174/0122115366298799240625115843.

Altered expression of miR-375 and miR-541 in type 2 diabetes patients with and without coronary artery disease (CAD): the potential of miR-375 as a CAD biomarker.

Sangali P, Abdullahi S, Nosrati M, Khosravi-Asrami O, Mahrooz A, Bagheri A J Diabetes Metab Disord. 2024; 23(1):1101-1106.

PMID: 38932834 PMC: 11196532. DOI: 10.1007/s40200-024-01391-w.

The role of MicroRNAs in the diagnosis and treatment of oral premalignant disorders.

Fathima J, Jayaraman S, Sekar R, Syed N Odontology. 2024; 112(4):1023-1032.

PMID: 38619695 DOI: 10.1007/s10266-024-00934-0.

References

Xu L, Li M, Wang M, Yan D, Feng G, An G . The expression of microRNA-375 in plasma and tissue is matched in human colorectal cancer. BMC Cancer. 2014; 14:714. PMC: 4181388. DOI: 10.1186/1471-2407-14-714. View

Zhou N, Qu Y, Xu C, Tang Y . Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Exp Ther Med. 2016; 11(2):625-630. PMC: 4734241. DOI: 10.3892/etm.2015.2920. View

Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T . Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer. DNA Cell Biol. 2014; 34(3):189-200. PMC: 4337462. DOI: 10.1089/dna.2014.2663. View

Zhang W, Gui J, Wang C, Chang Q, Xu S, Cai C . The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2013; 20(4):139-47. DOI: 10.3727/096504012x13522227232156. View

Yu H, Duan B, Jiang L, Lin M, Sheng H, Huang J . Serum miR-200c and clinical outcome of patients with advanced esophageal squamous cancer receiving platinum-based chemotherapy. Am J Transl Res. 2013; 6(1):71-7. PMC: 3853426. View

Li S, Gao Y, Wang Y, Wang K, Dai Z, Xu D . Serum microRNA-17 functions as a prognostic biomarker in osteosarcoma. Oncol Lett. 2017; 12(6):4905-4910. PMC: 5228414. DOI: 10.3892/ol.2016.5362. View

Menendez P, Padilla D, Villarejo P, Palomino T, Nieto P, Menendez J . Prognostic implications of serum microRNA-21 in colorectal cancer. J Surg Oncol. 2013; 108(6):369-73. DOI: 10.1002/jso.23415. View

Chen W, Gan T, Qin H, Huang S, Yang L, Fang Y . Implication of downregulation and prospective pathway signaling of microRNA-375 in lung squamous cell carcinoma. Pathol Res Pract. 2017; 213(4):364-372. DOI: 10.1016/j.prp.2017.01.007. View

Shi Z, Chu X, Wu Y, Wu J, Lu C, Lu R . MicroRNA-375 functions as a tumor suppressor in osteosarcoma by targeting PIK3CA. Tumour Biol. 2015; 36(11):8579-84. DOI: 10.1007/s13277-015-3614-9. View

10.

Mirabello L, Troisi R, Savage S . International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009; 125(1):229-34. PMC: 3048853. DOI: 10.1002/ijc.24320. View

11.

Laschi M, Bernardini G, Geminiani M, Ghezzi L, Amato L, Braconi D . Establishment of Four New Human Primary Cell Cultures from Chemo-Naïve Italian Osteosarcoma Patients. J Cell Physiol. 2015; 230(11):2718-27. DOI: 10.1002/jcp.24996. View

12.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

13.

Wang Z, Bian H, Wang J, Cheng Z, Wang K, De W . Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. J Surg Oncol. 2011; 104(7):847-51. DOI: 10.1002/jso.22008. View

14.

Selth L, Das R, Townley S, Coutinho I, Hanson A, Centenera M . A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2016; 36(1):24-34. DOI: 10.1038/onc.2016.185. View

15.

Rosen G, Caparros B, Huvos A, Kosloff C, Nirenberg A, Cacavio A . Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982; 49(6):1221-30. DOI: 10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e. View

16.

Lassalle S, Zangari J, Popa A, Ilie M, Hofman V, Long E . MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget. 2016; 7(21):30461-78. PMC: 5058693. DOI: 10.18632/oncotarget.8458. View

17.

Wu C, Li M, Hu C, Duan H . Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014; 41(3):1257-66. DOI: 10.1007/s11033-013-2970-z. View

18.

Fu H, Fu L, Xie C, Zuo W, Liu Y, Zheng M . miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. Oncol Rep. 2017; 37(2):1093-1099. DOI: 10.3892/or.2017.5360. View

19.

Yu H, Jiang L, Sun C, Li Guo L, Lin M, Huang J . Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. Gene. 2014; 534(1):60-5. View

20.

Zhou N, Wu J, Wang X, Sun Z, Han Q, Zhao L . Low-level expression of microRNA-375 predicts poor prognosis in hepatocellular carcinoma. Tumour Biol. 2015; 37(2):2145-52. DOI: 10.1007/s13277-015-3841-0. View